journal article·2018-01-02Open access

Down-regulation of MicroRNA-133 predicts poor overall survival and regulates the growth and invasive abilities in glioma

Yu Liu, Lili Han, Yahui Bai, Wei Du, Bo Yang

Abstract

miRNAs were reported as oncogene or tumour suppressors in various cancers and played important roles in tumour development and progression. Dysregulated miR-133 has been reported in several cancers, however, the expression and biological function of miR-133 in glioma remained unclear. In this study, we found that miR-133 expression level was significantly decreased in glioma tissues and cell lines by RT-qPCR. Then miR-133 mimics were used to evaluate the effects of miR-133 on cell proliferation and invasion in vitro. We found that overexpressed miR-133 could significantly suppress cell growth, and invasion in U87 cells. Additionally, we found that forkhead box C1 (FOXC1) was overexpressed in glioma tissue and it was directly regulated by miR-133. Overall, this study is the first proof to demonstrate that miR-133 function as tumour suppressor in glioma and inhibit cell proliferation and invasioned by directly targeting FOXC1, implying miR-133 as a potential therapeutic target for glioma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Circular RNAs in diseases · FOXO transcription factor regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;

Cancer Hospital of Henan Province, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China;

The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

References (39)

Show source-provided references
1. 10.1007/s13277-013-0756-510.1007/s13277-013-0756-5 ↗
2. 10.1080/21691401.2016.122617910.1080/21691401.2016.1226179 ↗
3. 10.3109/21691401.2015.111123710.3109/21691401.2015.1111237 ↗
4. 10.1016/j.critrevonc.2006.06.00710.1016/j.critrevonc.2006.06.007 ↗
5. 10.1056/NEJMoa04333010.1056/NEJMoa043330 ↗
6. 10.3109/21691401.2013.79435010.3109/21691401.2013.794350 ↗
7. 10.1080/21691401.2016.121685610.1080/21691401.2016.1216856 ↗
8. 10.3892/ol.2012.71410.3892/ol.2012.714 ↗
9. 10.3892/ol.2013.173710.3892/ol.2013.1737 ↗
10. 10.3892/ol.2012.84110.3892/ol.2012.841 ↗
11. 10.3892/ol.2014.232810.3892/ol.2014.2328 ↗
12. 10.3892/ol.2014.184110.3892/ol.2014.1841 ↗
13. 10.1016/j.bbrc.2016.08.08510.1016/j.bbrc.2016.08.085 ↗
14. 10.1158/0008-5472.CAN-12-431810.1158/0008-5472.CAN-12-4318 ↗
15. 10.1016/j.bbrc.2015.08.00710.1016/j.bbrc.2015.08.007 ↗
16. 10.3892/or.2015.435510.3892/or.2015.4355 ↗
17. 10.1371/journal.pone.006947810.1371/journal.pone.0069478 ↗
18. 10.1016/j.febslet.2012.08.00310.1016/j.febslet.2012.08.003 ↗
19. 10.1016/j.bbrc.2015.11.04610.1016/j.bbrc.2015.11.046 ↗
20. 10.1016/j.bbrc.2016.08.08510.1016/j.bbrc.2016.08.085 ↗
21. 10.3892/ijo.2012.174210.3892/ijo.2012.1742 ↗
22. 10.1371/journal.pone.001626410.1371/journal.pone.0016264 ↗
23. 10.1128/MCB.00743-0810.1128/MCB.00743-08 ↗
24. 10.1038/nprot.2007.3010.1038/nprot.2007.30 ↗
25. 10.1038/onc.2015.26010.1038/onc.2015.260 ↗
26. 10.1186/s12885-015-1449-910.1186/s12885-015-1449-9 ↗
27. Fakhoury M. · Artif Cells Nanomed Biotechnol · 2016 · 44 · 136510.3109/21691401.2015.1052467 ↗
28. 10.1007/s11060-014-1535-x10.1007/s11060-014-1535-x ↗
29. 10.1016/j.cellsig.2014.08.01210.1016/j.cellsig.2014.08.012 ↗
30. 10.1007/s13277-015-3637-210.1007/s13277-015-3637-2 ↗
31. 10.3892/or.2015.410110.3892/or.2015.4101 ↗
32. 10.3109/00365599.2012.74882110.3109/00365599.2012.748821 ↗
33. Tao J · Oncol Rep · 2012 · 27 · 1967
34. 10.1038/nrc222310.1038/nrc2223 ↗
35. 10.1245/s10434-014-3980-310.1245/s10434-014-3980-3 ↗
36. 10.1111/his.1234710.1111/his.12347 ↗
37. 10.1007/s13277-012-0629-310.1007/s13277-012-0629-3 ↗
38. 10.1002/ijc.2606010.1002/ijc.26060 ↗
39. 10.1007/s13402-014-0200-x10.1007/s13402-014-0200-x ↗